Adjuvant treatment with osimertinib significantly prolongs overall survival relative to placebo in people with EGFR -mutated, early-stage non-small-cell lung cancer, show trial results.

Osimertinib elicits high rates of systemic and intracranial response in people with advanced non-small-cell lung cancer harboring uncommon EGFR mutations, say the authors of the real-world UNICORN study.

Preliminary data from the INSIGHT 2 study suggest that the combination of tepotinib and osimertinib has activity in patients with EGFR -mutated advanced non-small-cell lung cancer with MET amplification who have progressed on first-line osimertinib.

Extended follow-up data from the ADAURA trial show that the disease-free survival benefit with adjuvant osimertinib over placebo continues beyond the 3-year treatment duration in people with EGFR -mutated stage IB–IIIA non-small-cell lung cancer.

With prior evidence suggesting that adjuvant EGFR-TKIs prolong disease-free survival (DFS) but not survival, the question is whether we can now rely on DFS to adopt adjuvant osimertinib in the clinic.

Disease-free survival benefit of osimertinib persists in patients with stage IB–IIIA EGFR -positive non-small-cell lung cancer regardless of adjuvant chemotherapy use, suggest exploratory analyses of the phase 3 ADAURA trial.

medwireNews : The EMA recommends adopting a new indication for osimertinib as adjuvant therapy for resectable early-stage non-small-cell lung cancer (NSCLC).

Second-line dacomitinib treatment is associated with a low objective response rate among patients with EGFR -mutated non-small-cell lung cancer who progress on first-line osimertinib, report US researchers.

A review of data from the osimertinib clinical trials program has not identified a causal relationship between the use of the EGFR–tyrosine kinase inhibitor and cardiotoxicity among patients with advanced non-small-cell lung cancer.

Health-related quality of life is maintained during long-term treatment with adjuvant osimertinib in people with resected, EGFR -mutated non-small-cell lung cancer, research shows.

Adding bevacizumab to osimertinib therapy does not improve progression-free survival for patients with advanced non-small-cell lung cancer harboring an EGFR T790M mutation, phase 2 study data suggest.

Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR -mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.

The phase 3 AURA3 trial has failed to demonstrate a significant overall survival gain with second-line osimertinib versus platinum–pemetrexed in patients with advanced non-small-cell lung cancer carrying the EGFR T790M resistance mutation.

The FLAURA trial comparing osimertinib with erlotinib or gefitinib in the first-line treatment of EGFR -mutated, advanced non-small-cell lung cancer has shown positive overall survival results favoring the third-generation EGFR–tyrosine kinase inhibitor.

Suresh Ramalingam presents the overall survival analysis of the FLAURA trial of osimertinib in EGFR mutation-positive, advanced non-small-cell lung cancer, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).

Combining osimertinib with gefitinib has promising efficacy and tolerability in treatment-naïve patients with metastatic EGFR -mutated non-small-cell lung cancer, suggest early data presented at the virtual 2020 ASCO Annual Meeting.

Patients with stage IB–IIIA non-small-cell lung cancer harboring EGFR mutations derive a significant disease-free survival benefit from adjuvant treatment with osimertinib, shows the phase 3 ADAURA trial.

Around 5% of non-small-cell lung cancer patients using osimertinib monotherapy may experience severe cardiac adverse events, suggests a study of Japanese patients.

Patients with EGFR -mutant non-small-cell lung cancer and leptomeningeal metastases respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest.

Individuals with advanced non-small-cell lung cancer harboring uncommon EGFR mutations have favorable outcomes in response to osimertinib treatment, say Korean researchers.